HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN priorities

This article was originally published in The Rose Sheet

Executive Summary

Revitalization of FDA's cosmetics program cited among Center for Food Safety and Applied Nutrition's fiscal 2003 program priority accomplishments. Office of Cosmetics & Colors met with stakeholders to gain input on revitalization efforts, and as a result, the office has "developed priority activities that will be highlighted and implemented in CFSAN's FY 2004 program priorities," the center announces in its year-end "report card," released Nov. 24. Development of a Web-based voluntary cosmetic registration program, draft labeling guidance for cosmetics containing alpha hydroxy acids also cited as program accomplishments. Likewise, the office analyzed all color additive batches and determined certification status in an average of five working days, FDA adds. During the year, CFSAN completed 92% of its "A" list priorities, with the majority focused on bioterrorism and food safety initiatives...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS011703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel